Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment goals for AS include alleviating signs and symptoms, improving physical function, preventing disability, and slowing or preventing structural damage. TNF-alpha inhibitors such as AbbVie’s Humira, Amgen’s Enbrel, Johnson & Johnson Innovative Medicine’s Remicade and Simponi / Simponi Aria, UCB’s Cimzia, and infliximab biosimilars can effectively reduce disease activity in AS particularly in patients who require potent therapies beyond first-line nonsteroidal anti-inflammatory drugs (NSAIDs). Recently launched adalimumab biosimilars offer cost-effective alternatives while maintaining similar efficacy and safety profile. The IL-17 inhibitors—Novartis’s Cosentyx, Eli Lilly’s Taltz and recently approved, UCB’s Bimzelx—offer an alternative MOA to TNF inhibition. The novel JAK inhibitor class comprises Pfizer’s Xeljanz and AbbVie’s Rinvoq, which are the only nonbiological targeted therapies for AS.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AS patients?
- How has Rinvoq been integrated into the treatment algorithm, and what is its source of business?
- What percentage of AS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of AS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Humira, Enbrel, Cimzia, Remicade, Simponi, Cosentyx, Taltz, Xeljanz, Rinvoq, NSAIDs
Key analyses: Brand / therapy usage across longitudinal patient sample, newly diagnosed patient analysis, treatment initiation and progression, line of therapy analysis, combination therapy analysis, source of business for recently treated patients, persistency and compliance analysis, product-level patient flow charts
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
